alexa Progress In Diagnosis And Treatment Of Advanced NK/T Cell Lymphoma
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

7th World Hematologists Congress
May 08-09, 2017 Barcelona, Spain

Mingzhi Zhang
First Affiliated Hospital of Zhengzhou University, China
ScientificTracks Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-022
Natural killer/T-cell lymphoma (NKTCL) is a subtype of non-Hodgkin’s lymphoma, which has a higher incidence in East-Asia compared with United States and Europe. This tumor is characterized by highly aggressive nature, rapid progression and poor survival. However, optimal treatment strategies for advanced NKTCL have not been defined. Traditional CHOP and CHOP-like regiments usually provide poor clinical outcomes. Recently, L-asparaginase (L-Asp) based regimen including dexamethasone, methotrexate, ifosfamide, L-Asp and etoposide (SMILE) has been devised and showed a relatively improved efficacy, but at the same time, severe hematologic toxicity were seen. We formulated a novel pegaspargase based chemotherapy regimen: dexamethasone, cisplatin, gemcitabline, pegaspargase (DDGP) and performed clinical trial (No. NCT01501149). Patients were newly diagnosed in stage III-IV and had performance scores in 0-2. Six cycles of DDGP or SMILE chemotherapy were randomly assigned to them. In conclusion, DDGP chemotherapy resulted in significant improvement in one-year PFS (86% versus 38%, P=0.006), two-year OS (74% versus 45%, P=0.027) and better tolerability compared with SMILE chemotherapy. We also discussed and elucidated the mechanisms concerned with the better effect of DDGP on DNA damage, nucleic acid metabolism, and ATP-binding cassette transportersdependent multidrug resistance. In addition, we are making great efforts to explore new approaches including hematopoietic stem cell transplantation with a unique induction chemotherapy and application of PD-1 immune checkpoint inhibitor, which greatly benefit the patients after chemotherapy failure.

Mingzhi Zhang completed his PhD at Zhengzhou University Medical School. He is the Director of Lymphoma Diagnosis and Treatment Center in Henan Province and Department of Oncology, The First Affiliated Hospital of Zhengzhou University. He has published more than 30 papers in reputed journals and achieved honors and awards on Lymphoma Research in China.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version